the patient presents ( Figure 40 and Table 26 ). Using target haemoglobin relative to the remaining renal failure population. Patients with a haemoglobinopathy month 1 data, the epoetin dose was consistently higher for haemodialysis patients than for peritoneal dialysis had significantly lower target haemoglobin levels than other patients with chronic renal failure who did not patients across all concomitant pathologies. The variability of epoetin dose for peritoneal dialysis patients have a haemoglobinopathy (t=−2.345, df=13 641, P<0.05) ( Figure 41 , Table 27 ). was also consistently lower than for haemodialysis patients, as shown by the smaller standard deviations EBPG 14 recommends evaluation and, if reversible, treatment of infection/inflammation. Figure 42 sumacross all concomitant pathologies. A subsample of interest was a group of patients with a haemo-marizes data on epoetin dose and haemoglobin level, stratified by CRP levels: ∏10.0 mg/l (n=3612), globinopathy, who were reviewed for differences in 10.1-50.0 mg/l (n=1594), 50.1-100.0 mg/l (n=248) and >100.0 mg/l (n=124). Differences in month 1 mean epoetin dose by CRP category are statistically significant (F=34.1, df=3, P<0.001). The dose increases from 104.3 IU/kg/week for the ∏10.0 mg/l category to 146.0 IU/kg/week for the >100 mg/l category. Month 1 haemoglobin also varies significantly in relation to CRP category (F=17.894, df=3, P<0.001), with haemoglobin decreasing across the first three CRP categories (from 11.1 g/dl for the ∏10 mg/l category to 10.6 g/dl for the >100 mg/l category).
The database was then censored by eliminating patients with CRP levels of ∏10 mg/l (n=1966). Again using month 1 data, there was a very weak but (due to the sample size) significant correlation between month 1 CRP levels and epoetin dose (r=0.077, P<0.01). Considering, therefore, that CRP level accounts for a minimal 0.6% of the variance in epoetin dose, the absence of an association between infection and dose within a single month may be inferred. This deduction seems warranted given also the very low correlation (r=0.078) between month 1 CRP level and month 2 epoetin dose (explained variance=0.6%). However, when stratified on chronic infection/ inflammation, defined as a CRP level Á50 mg/l on any three or more months, there is consistently a statistically significant difference in epoetin dose. Figure 43 shows the difference in both epoetin dose and achieved haemoglobin between patients classified as having chronic infection/inflammation and those without chronic infection/inflammation.
Concomitant therapies
It has been suggested that concomitant therapies and vitamin supplementation may influence the response to epoetin therapy, although there are limited scientific data to support this. For example, the influence of ACE inhibitors on both absolute haemoglobin concentrations and response to epoetin therapy has been controversial in the literature [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Figure 44 illustrates the difference in mean epoetin dose (in the maintenance phase) by use of ACE inhibitors vs nonuse both within dialysis groups and across dialysis groups. Prior to stratification by ACE inhibitor use, epoetin dose was significantly higher in haemodialysis patients. This holds true in both the use of ACE inhibitor group and the non-use group. Epoetin dose differences between ACE users and non-users were significant for peritoneal dialysis patients. Differences in maintenance epoetin dose and haemoglobin level between ACE inhibitor users and non-users are shown for all months in Table 28 . Differences between the mean haemoglobin of ACE users and non-users range from 0 to 0.1 g/dl, and those for mean epoetin dose ranged from 0.4 to 1.8 IU/kg/week.
Another subsample of interest which was evaluated was those patients receiving enalapril, the ACE inhibitor used most frequently in the dialysis population. Table 29 provides the monthly breakdown of haemo- globin and epoetin dosage by monthly enalapril dose according to the monthly categorization of enalapril.
Within all three variables (target haemoglobin, (5 mg/day and 20 mg/day). The monthly achieved haemoglobin and epoetin dose variables correspond to achieved haemoglobin and epoetin dose), and within all months, the values increased between those the same month in which enalapril was evaluated. The target haemoglobin, however, was recorded only upon receiving 5 mg/day of enalapril and those receiving 20 mg/day. None of these differences is statistically enrolment into ESAM but was evaluated repeatedly significant, however, with the exception of month 1 tations had any influence on either haemoglobin or epoetin dose. haemoglobin.
Use of vitamins, folate and -carnitine supplementation was assessed for the entire ESAM sample Comments ( Table 30 ). There was considerable variability of supplementation across countries especially with regard to vitamin B 12
, vitamin C and -carnitine. The most common cause of inadequate response to epoetin therapy is absolute or functional iron deficiency Vitamin D and folic acid are the most frequently utilized supplementations. None of these supplemen- [14] . Of 313 patients receiving Á300 IU/kg/week of epoetin ( Figure 39 ), 36 patients had absolute iron deficiency and 87 of 223 patients with transferrin saturation measurements had functional iron deficiency. The mean serum ferritin level (481.2±472.9 mg/l ) and mean transferrin saturation (25.1±13.2%) reflect, however, 'adequate' iron status for the whole group of patients with an inadequate response to epoetin.
The mean CRP levels were greater in patients receiving the high maintenance dose of epoetin as compared with those receiving the lower dose ( Table 25) . At month 1, data on epoetin doses and haemoglobin levels increase and decrease, respectively, with each successively higher CRP category (Figure 42 ). CRP levels Á50 mg/l on three or more months result in significantly higher epoetin requirements and lower haemoglobin levels throughout the study period of 6 months as compared with haemodialysis patients with CRP levels <50 mg/l on four or more months (Figure 43) . Bárány et al. [15] have also shown that elevated CRP values are associated with higher dose requirements of epoetin to keep the target haemoglobin values constant.
The achieved haemoglobin levels of patients with neoplasia or hepatitis were almost the same as for the entire sample, but epoetin doses were higher ( Figure 40 , Table 26 ). These findings are probably due to excessive cytokine production which reduces the epoetin response [16 ] . Other factors known to influence the response to epoetin were not different between the groups receiving <300 IU/kg/weekly or Á300 IU/kg/weekly ( Table 25) .
Differences in epoetin dose were not observed between ACE inhibitor users and non-users for haemodialysis patients but were observed (at P<0.05) for CAPD patients (Figure 44 , see also Table 28 ). The effect of ACE inhibitors on both haemoglobin concentrations and response to epoetin therapy has been controversial [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Erturk et al. [17] switched ACE inhibitors to another antihypertensive medication in 23 out of 68 hypertensive haemodialysis patients receiving epoetin and an ACE inhibitor for >1 year. Withdrawal of ACE inhibitors resulted in an increase in haemoglobin level, and a decrease in epoetin dose. The inhibitory effect of ACE inhibitors on the action of epoetin is most apparent when high doses of ACE inhibitors are used, particularly if the patient is on a low dose of epoetin. However, neither 5 nor 20 mg of enalapril per day had a significant impact on epoetin response in the study presented here ( Table 29) . Macdougall [18] recommended that the indication for the ACE inhibitor therapy be reviewed if there is an inadequate response to epoetin. Switching to an alternative drug may be easier when used for treating hypertension than when used for treating patients with left ventricular dysfunction or diabetic nephropathy. Consistent with ESAM data, the dose or duration of ACE inhibitor therapy did not affect haemoglobin or haematocrit level in the study of Charytan et al. [19] . The authors concluded that ACE inhibitor therapy does not appear to affect the response to epoetin in epoetin dose levels. Considerable variability exists with regard to vitamin B 12 , vitamin C and -carnitine chronic dialysis patients.
Because ESAM is a prospective survey and not an supplementation across Europe. interventional trial, we cannot consider these results as absolute proof of the non-interference of ACE inhib-References itors with haemoglobin and epoetin dose. However, we can conclude that in this large population no 
